Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.5.584 · Cited by 3,991

The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer

Postmus, P. E., Brambilla, E. M., Chansky, K., Crowley, J. J., Goldstraw, P. G., Patz, E. F., & Yokomise, H. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31811f4703 · Cited by 1,593

Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience

Vitale, G., Lamberti, G., Comito, F., Nunno, V. D., Massari, F., Morelli, M. C., Ardizzoni, A., & Gelsomino, F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1762562 · Cited by 14

Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents

Freitas, C., Jacob, M., Tavares, N., Martins, N. A., Souto-Moura, C., Araújo, D., Bastos, H. N., Santos, V., Fernandes, G., Magalhães, A., et al. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001060 · Cited by 14

Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study

Fujimoto, A., Koutake, Y., Hisamatsu, D., Ookubo, N., Yabuuchi, Y., Kamimura, G., Kai, T., Kozono, A., Ootsu, T., Suzuki, H., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03408-4 · Cited by 14

Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype

Takada, K., Toyokawa, G., Kinoshita, F., Jogo, T., Kohashi, K., Wakasu, S., Ono, Y., Tanaka, K., Oba, T., Osoegawa, A., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03250-6 · Cited by 14

Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors

Holstead, R. G., Kartolo, B., Hopman, W. M., & Baetz, T. D. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000736 · Cited by 14

Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer

Ushio, R., Yamamoto, M., Miyasaka, A., Muraoka, T., Kanaoka, H., Tamura, H., Kaneko, A., Izawa, A., Hirama, N., Teranishi, S., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6410-20 · Cited by 14

The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol

Greenstein, A. E., & Hunt, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110312 · Cited by 13

Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients

Yan, D. (2023) · Biomedicines · doi:10.3390/biomedicines11112916 · Cited by 12

Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios

Tay, R. Y., Prelaj, A., & Califano, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.80 · Cited by 13

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

Pantano, F., Russano, M., Berruti, A., Mansueto, G., Migliorino, M. R., Adamo, V., Aprile, G., Gelibter, A. J., Ficorella, C., Falcone, A., et al. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1724953 · Cited by 13

Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade

Shen, Y., Chen, Y., Wang, D., & Zhu, Z. (2020) · Medicine · doi:10.1097/md.0000000000022153 · Cited by 13

A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen

Yin, J., Wen, M., Cheng, J., Hu, L., Yang, L., Chang, X., Zhou, Z., Li, H., Liu, Y., & Li, J.-B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.712466 · Cited by 13

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy

Sayer, M. R., Mambetsariev, I., Lu, K., Wong, C. W., Duche, A., Beuttler, R., Fricke, J., Pharoan, R., Arvanitis, L. D., Eftekhari, Z., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1064169 · Cited by 13

Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma

Yamamoto, Y., Matsuyama, H., Matsumoto, H., Sakano, S., Fuji, N., Oba, K., Yamamoto, M., Kamiryo, Y., Hiragino, T., Nagao, K., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz168 · Cited by 13

Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer

Ida, H., Goto, Y., Sato, J., Kanda, S., Shinno, Y., Morita, R., Murakami, S., Matsumoto, Y., Yoshida, T., Horinouchi, H., et al. (2020) · Medical Oncology · doi:10.1007/s12032-020-01357-x · Cited by 13

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial

Botticelli, A., Mezi, S., Pomati, G., Sciattella, P., Cerbelli, B., Roberto, M., Mammone, G., Cirillo, A., Cassano, A., Dio, C. D., et al. (2020) · Vaccines · doi:10.3390/vaccines8020191 · Cited by 13

The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors

Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Ono, Y., Tagawa, T., Okamoto, T., Hamatake, M., Okamoto, I., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263247 · Cited by 12

Immune-Related Adverse Events in Patients with Lung Cancer

Correia, G. S. D. C., Pai, T., Li, S., Connor, D., Zhao, Y., Lou, Y., & Manochakian, R. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01462-w · Cited by 12

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

Cortellini, A., Buti, S., Bersanelli, M., Giusti, R., Perrone, F., Marino, P. D., Tinari, N., Tursi, M. D., Grassadonia, A., Cannita, K., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1710389 · Cited by 12

Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index

Franco, A. O., Hodgson, C., Raja, H., Carter, M., Lindsay, C. R., Hughes, S., Cove-Smith, L., Taylor, P. D., Summers, Y., Blackhall, F. H., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00889-8 · Cited by 12

Plasma D‐dimer and interleukin‐6 are associated with treatment response and progression‐free survival in advanced NSCLC patients on anti‐ PD ‐1 therapy

Chen, C., Yin, H., Zhang, Y., Chen, H., Xu, J., & Ren, L. (2023) · Cancer Medicine · doi:10.1002/cam4.6222 · Cited by 12

Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma

Nakamura, K. D., Okubo, K., Takahashi, T., Mitsumori, K., Ishigaki, T., & Ohnishi, H. (2018) · IJU Case Reports · doi:10.1002/iju5.12032 · Cited by 12

Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan

Chen, Y.-M., Yang, J. C., Su, W., Chong, I., Hsia, T., Lin, M.-C., Chang, G., Chiu, C., Ho, C., Wu, S., et al. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.01.004 · Cited by 12

Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Sano, A., Sohda, M., Nakazawa, N., Ubukata, Y., Kuriyama, K., Kimura, A., Kogure, N., Hosaka, H., Naganuma, A., Sekiguchi, M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-021-09118-3 · Cited by 12

Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer

Umehara, K., Yama, K., Goto, K., Wakamoto, A., Hatsuyama, T., Honjo, O., Saikai, T., 藤田, 昭., & Sato, H. (2021) · Cancer Control · doi:10.1177/1073274820985790 · Cited by 11

Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases

AKANO, Y., Kuribayashi, K., Funaguchi, N., Koda, Y., Fujimoto, E., Mikami, K., Minami, T., Takahashi, R., Yokoi, T., & Kijima, T. (2019) · In Vivo · doi:10.21873/invivo.11503 · Cited by 11

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Remón, J., Esteller, L., & Taus, Á. (2019) · Cancer Management and Research · doi:10.2147/cmar.s164935 · Cited by 12

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient

Yatsuda, Y., Hirose, S., Ito, Y., Onoda, T., Sugiyama, Y., Nagafuchi, M., Suzuki, H., Niisato, Y., Tange, Y., Ikeda, T., et al. (2020) · Internal Medicine · doi:10.2169/internalmedicine.5893-20 · Cited by 11

Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902)

Ito, S., Asahina, H., Honjo, O., Tanaka, H., Honda, R., Oizumi, S., Nakamura, K., Takamura, K., Hommura, F., Kawai, Y., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.011 · Cited by 11

A Case of Cancer-Associated Hyponatraemia: Primary Adrenal Insufficiency Secondary to Nivolumab

Galliazzo, S., Morando, F., Sartorato, P., Bortolin, M., & Menis, E. D. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530321666210708142815 · Cited by 11

The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients

Allegra, A., Salvo, E. D., Casciaro, M., Musolino, C., Pioggia, G., & Gangemi, S. (2020) · Biomedicines · doi:10.3390/biomedicines9010002 · Cited by 10

Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival

Adda, L., Batteux, B., Saidak, Z., Poulet, C., Arnault, J., Chauffert, B., & Séjourné, A. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105168 · Cited by 11

Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis

Mayer, K. T., Briese, W., Blieninger, J., Brossart, P., Bisht, S., & Feldmann, G. (2021) · Oncology Research and Treatment · doi:10.1159/000518449 · Cited by 10

Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy

Maetani, T., Hamaguchi, T., Nishimura, T., Marumo, S., & Fukui, M. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7644-21 · Cited by 10

Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study

Kataoka, Y., Hirano, K., Narabayashi, T., Hara, S., Fujimoto, D., Tanaka, T., Ebi, N., Tomii, K., & Yoshioka, H. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3498-z · Cited by 10

Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer

Ishizuka, Y., Narita, Y., Sakakida, T., Wakabayashi, M., Kodama, H., Honda, K., Masuishi, T., Taniguchi, H., Kadowaki, S., Ando, M., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251339921 · Cited by 9

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report

Wang, J., Li, Q., Lv, H., Nie, C., Chen, B., Xu, W., Yang, T., Zhang, Y., Tu, S., & Chen, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671416 · Cited by 9

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators

Stellato, M., Procopio, G., Giorgi, U. D., Maruzzo, M., Bimbatti, D., Mennitto, A., Sbrana, A., Roviello, G., Casadei, C., Sepe, P., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03008-9 · Cited by 10

Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment

Choi, M. G., Choi, C., Lee, D. H., Kim, S., Yoon, S., Ji, W., & Lee, J. C. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-146 · Cited by 9

Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma

Hamada, S., Fuseya, Y., & Tsukino, M. (2018) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2018.01.026 · Cited by 9

Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature

Li, H., Zhou, X. M., Zhang, D., Wang, G., Cheng, X., Xu, C., Yao, B., Pang, L., & Chen, J. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00366 · Cited by 9

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey

Hata, H., Mio, T., Yamashita, D., Matsumura, C., Chisaki, Y., Motohashi, H., & Yano, Y. (2020) · Cancer Control · doi:10.1177/1073274820977200 · Cited by 8

Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review

Abdihamid, O., Athman, A., & Rugambwa, T. K. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1314 · Cited by 9

Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness

Cortijo‐Cascajares, S., Cercós-Lletí, A. C., Ortiz-Pérez, S., Teller, J. M. C., & Ferrari-Piquero, J. M. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211067429 · Cited by 8

Association of Geriatric Nutritional Risk Index With Immune Checkpoint Inhibitor Treatment Duration and Adverse Events in Lung Cancer

SHIMIZU, A., FUKASAWA, M., Mitani, K., GOTO, K., Wakamoto, A., Hatsuyama, T., HOSHI, T., Hasegawa, I., & Sato, H. (2023) · In Vivo · doi:10.21873/invivo.13454 · Cited by 8

Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study

Liguori, L., Giorgio, G., Polcaro, G., Pagliara, V., Malandrino, D., Perri, F., Cascella, M., Ottaiano, A., Conti, V., Servetto, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419544 · Cited by 8

Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors

Oyanagi, J., Koh, Y., Sato, K., Teraoka, S., Tokudome, N., Hayata, A., Akamatsu, H., Ozawa, Y., Nakanishi, M., Ueda, H., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.007 · Cited by 7

Nivolumab in non–small cell lung cancer: A novel case of an erythema annulare centrifugum–like eruption

Sidiropoulou, P., Sgontzou, T., Κωστάρα, Ι., Sgouros, D., Theologi, B., Zouridaki, E., Kontochristopoulos, G., Rigopoulos, D., & Stratigos, A. (2019) · JAAD Case Reports · doi:10.1016/j.jdcr.2019.04.007 · Cited by 8

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors

Argnani, L., Casadei, B., Pelusi, C., Preiato, V. L., Pagotto, U., Bertoni, F., & Zinzani, P. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-05861-0 · Cited by 8

Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer

Soto, C. M. V., Palomares, M. V. V., Fernández-Cueto, A. G.-A., Villanueva, S. B., Callejo, V. M., Sufrategui, M. O., Muñoz, P., & Domínguez, M. V. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-003038 · Cited by 7

Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: A case report and literature review

Marco, A. D., Artioli, G., Favaretto, A. G., Cavasin, N., & Basso, U. (2024) · Medicine · doi:10.1097/md.0000000000037606 · Cited by 7

The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK

Vasiliadou, I., Grose, D., Wilson, C., Thapa, A., Donnelly, O., Lee, E., Leslie, I., Karim, M., Hartley, A., Partridge, S., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34963 · Cited by 9

Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival

Chilelli, M. G., Signorelli, C., Berrìos, J. R. G., Onorato, A., Nelli, F., Fabbri, A., Primi, F., Marrucci, E., Virtuoso, A., Schirripa, M., et al. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10076 · Cited by 7

Simultaneous Pseudoprogression and an Immune-related Adverse Event of Pulmonary Pleomorphic Carcinoma after Combined Therapy with Cytotoxic Anticancer Agents and Immune Checkpoint Inhibitor

Murao, K., Mori, Y., Takahashi, Y., Ishikawa, T., Asai, Y., Kobayashi, T., Ikeda, K., Kuronuma, K., Magara, K., Fujita, H., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8916-21 · Cited by 7

Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review

Tan, Q., Liu, L., Huang, Y., Dong, X., & Chen, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973421 · Cited by 7

Case report: A case of fulminant type 1 diabetes mellitus after COVID-19 vaccination during treatment of advanced gastric cancer: pitfall in managing immune-related adverse events

Tanaka, T., Nagasu, S., Furuta, T., Gobaru, M., Suzuki, H., Shimotsuura, Y., Akiba, J., Nomura, M., Fujita, F., Kawaguchi, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1264281 · Cited by 7

Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis

Zhao, J., Feng, Y., & Liu, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27832 · Cited by 7

The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

Tanimura, K., Yamada, T., Chihara, Y., Kubota, Y., Shiotsu, S., Takeda, T., Yamada, T., Hiranuma, O., Uchino, J., & Takayama, K. (2019) · Haigan · doi:10.2482/haigan.59.128 · Cited by 7

Development of a protein-based system for transient epigenetic repression of immune checkpoint molecule and enhancement of antitumour activity of natural killer cells

Teratake, Y., Takashina, T., Iijima, K., Sakuma, T., Yamamoto, T., & Ishizaka, Y. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0708-y · Cited by 7

Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non–small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report

Riudavets, M., Caramella, C., Pradère, P., Naltet, C., Pechoux, C. L., Adam, J., Mabille, L., Rouleau, É., Besse, B., & Planchard, D. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.011 · Cited by 7

Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Takamori, S., Takada, K., Shimokawa, M., Jinnnouchi, M., Matsubara, T., Haratake, N., Miura, N., Toyozawa, R., Yamaguchi, M., Takenoyama, M., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02783-6 · Cited by 8

Immune-related adverse events with immune checkpoint inhibitors

Hirata, A., Saraya, T., Kobayashi, F., Noda, A., Aso, K., Sakuma, S., Kurokawa, N., Inoue, M., Mikura, S., Oda, M., et al. (2021) · Medicine · doi:10.1097/md.0000000000025275 · Cited by 7

Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204

Toi, Y., Kobayashi, T., Harada, T., Nakagawa, T., Mori, Y., Kuda, T., & Sugawara, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685320 · Cited by 7

Pembrolizumab‑induced aseptic meningitis in a patient with non‑small cell lung cancer: A case report and literature review of aseptic meningitis as an immune‑related adverse event

Inui, G., Funaki, Y., Makino, H., Touge, H., Arai, K., Kuroda, K., Hirayama, Y., Kato, R., Nonaka, T., Yamane, K., et al. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2553 · Cited by 6

Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer

Kim, H. I., Kim, W. G., Kim, M., Ko, N. G., Jin, M., Jung, H. A., Sun, J., Ahn, J. S., Ahn, M., Choi, Y., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03852-w · Cited by 6

The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients

Radwan, A., Jani, C., Omari, O. A., Patel, M., Burns, L., Mackay, Z., Li, L., Mahdaviani, K., Davidson, A., Weinberg, J., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae279 · Cited by 6

Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning

Pan, S., & Wang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1516524 · Cited by 6

The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials

Liu, Q., Fang, Z., Liu, M., Xu, R., Yi, F., Wei, Y., Zeng, L., & Zhang, W. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13465 · Cited by 6

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors

Zou, X.-L., Chen, W.-Y., Zhang, G., Ke, H., Yang, Q., & Li, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.747075 · Cited by 6

Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer

Gannichida, A., Nakazawa, Y., Kageyama, A., Utsumi, H., Kuwano, K., & Kawakubo, T. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i7.641 · Cited by 6

Lung adenocarcinoma with tumor resolution and dystrophic calcification after salvage surgery following immune checkpoint inhibitor therapy: A case report

Sumi, T., Uehara, H., 正岡, 俊., Tada, M., Keira, Y., Kamada, K., Shijubou, N., Yamada, Y., Nakata, H., Mori, Y., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13663 · Cited by 6

Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature

Liu, C., Piao, J., & Shang, Z. (2021) · BMC Urology · doi:10.1186/s12894-021-00813-8 · Cited by 6

Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors

Zhong, X., Ying, J., Liao, H., Shen, L., & Pan, Y. (2022) · Future Oncology · doi:10.2217/fon-2021-1537 · Cited by 6

Predictive and prognostic impact of primary tumor‐bearing lobe in nonsmall cell lung cancer patients treated with anti‐PD ‐1 therapy

Takamori, S., Takada, K., Shimokawa, M., Matsubara, T., Haratake, N., Miura, N., Toyozawa, R., Yamaguchi, M., Takenoyama, M., Yoneshima, Y., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33030 · Cited by 6

Surrogate endpoints in immunotherapy trials for solid tumors

Petrelli, F., Ghidini, M., Costanzo, A., Rampulla, V., Varricchio, A., & Tomasello, G. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.03.20 · Cited by 6

Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor–Associated Pneumonitis in Patients With Lung Cancer

Li, X., Yang, F., Liu, B., Ye, L., Du, J., Fan, X., Yu, Y., Li, M., Bu, L., Zhang, Z., et al. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000515 · Cited by 5

Immune-related [18F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications

Santo, G., Cucè, M., Restuccia, A., Giudice, T. D., Tassone, P., Cicone, F., Tagliaferri, P., & Cascini, G. L. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00774-9 · Cited by 5

Immune Checkpoint Inhibitor Associated Rheumatoid Arthritis

Bernabela, L., & Bermas, B. L. (2024) · Current Rheumatology Reports · doi:10.1007/s11926-024-01173-6 · Cited by 5

Clinical and radiological features of pseudoprogression in brain tumors treated with immune checkpoint inhibitors

Ibáñez-Juliá, M.-J., Bataller, L., Murgui, F. C., Them, L. N., Alentorn, A., Torres-Martínez, A., Mazón, M., & Sarrió, R. G. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05091-0 · Cited by 5

Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab?

Kuş, T., & Aktaş, G. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219877923 · Cited by 5

High intramuscular adipose tissue content was a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab monotherapy

Tanaka, T., Miwa, K., Shimotsuura, Y., Nagasu, S., Shigyou, H., Hirota, K., Koya, S., Akagi, Y., & Kawaguchi, T. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16239 · Cited by 5

The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study

Huang, H. F., Chen, R., Xu, Y., Fang, N., Shao, C., Xu, K. L., & Wang, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010255 · Cited by 5

The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis

Yang, Y., Pang, P., Xie, Z., Wang, N., Liang, H., & Zhao, L. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.82 · Cited by 5

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report

Kato, M., Mori, M., Miura, K., Asao, T., Motomura, H., Nishino, K., Ko, R., Koyama, R., Hayashi, T., & Takahashi, K. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14185 · Cited by 4

Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma

Chen, Y., Zhuang, L., Zhang, D., Du, X., & Sheng, L. (2022) · Journal of Immunology Research · doi:10.1155/2022/4015897 · Cited by 5

Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab

Lefort, F., Dalban, C., Gross‐Goupil, M., Laguerre, B., Chabaud, S., Escudier, B. J., & Albiges, L. K. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2296 · Cited by 5

Morphological changes of the thyroid gland as a new radiographic marker for lung cancer treatment efficacy of immune checkpoint inhibitors

Itonaga, T., Saito, K., Ikeda, N., & Mikami, R. (2020) · Acta Radiologica · doi:10.1177/0284185120916197 · Cited by 5

A retrospective analysis of immune checkpoint inhibitors in patients with preexisting organ dysfunction

Kesireddy, M., Marr, A., Schissel, M. E., & Ganti, A. K. (2023) · Cancer · doi:10.1002/cncr.34958 · Cited by 4

Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

Chen, D., Saltos, A. N., Rose, T. A., Thompson, Z., Thapa, R., Chiappori, A., & Gray, J. E. (2023) · Cancers · doi:10.3390/cancers15092521 · Cited by 4

Severe oral ulcerative and lichenoid lesions associated with adrenal insufficiency in a patient treated with nivolumab: Report of a case and review of literature

Gobbi, M. F., Eduardo, F. D. P., Bezinelli, L. M., de Carvalho, D. L. C., do Vale, S. K. M., & Côrrea, L. (2021) · Special Care in Dentistry · doi:10.1111/scd.12660 · Cited by 4

Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients

Higashiyama, R. I., Horinouchi, H., Kuchiba, A., Matsumoto, Y., Murakami, S., Goto, Y., Kanda, S., Fujiwara, Y., Yamamoto, N., & Ohe, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04205-9 · Cited by 4

Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study

Difoum, F. L., Schernberg, A., Vanquaethem, H., Picchi, H., Roy, A. L., Vuagnat, P., & Hélissey, C. (2022) · Cancer Reports · doi:10.1002/cnr2.1760 · Cited by 4

A retrospective multicentric cohort study of checkpoint inhibitors‐induced pruritus with focus on management

Papageorgiou, C., Lazaridou, E., Lallas, K., Papaioannou, K., Nikolaou, V. A., Mateeva, V., Efthymiadis, K., Koukoutzeli, C., Loga, K., Sogka, E., et al. (2023) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/phpp.12892 · Cited by 4

Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy

Asher, N., Bar-Hai, N., Ben‐Betzalel, G., Stoff, R., Grynberg, S., Schachter, J., Steinberg‐Silman, Y., Gelernter, L., Shlasky, A., & Frommer-Shapira, R. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000000985 · Cited by 4

Is the onset of adverse effects of immunotherapy always bad news for the patients…?—certainly not!

Hofman, P. M. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.14 · Cited by 4

A case of nivolumab-induced cervical lymphadenopathy in a patient with gastric cancer

Taira, K., Kimura, A., Nakata, A., Nadatani, Y., Fukunaga, S., Otani, K., Hosomi, S., Tanaka, F., Kamata, N., Nagami, Y., et al. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-315 · Cited by 4

Endocrine immune-related adverse events: a double-edged sword?

Rengarajan, M., & Gainor, J. F. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-2020-16 · Cited by 3

Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity

Pellitero, A. M., García, M. Z., Ruiz, M. G., Arbonés-Mainar, J. M., del Prado, R. L., & Isla, D. (2024) · World Journal of Oncology · doi:10.14740/wjon1790 · Cited by 3

Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer

Takamori, S., Shimokawa, M., Yamaguchi, M., Mori, M., Kuyama, S., Oki, M., Nishimura, Y., Nakatomi, K., Yanai, H., Sukoh, N., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70170 · Cited by 3

Observation on the Therapeutic Efficacy of Camrelizumab Combined with Chemotherapy in Non-small Cell Lung Cancer and the Cutaneous Immune-related Adverse Events: A Retrospective Study

Wang, H., Xia, J., Yü, A., Cao, M., Yang, Z., Qin, X., Liu, W., Han, Z., & Jiang, G. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206350978241105080452 · Cited by 3

Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Hosoya, K., Fujimoto, D., Morimoto, T., Kumagai, T., Tamiya, A., Taniguchi, Y., Yokoyama, T., Ishida, T., Hirano, K., Matsumoto, H., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.003 · Cited by 43

Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab

Toi, Y., Sugawara, S., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Tsurumi, K., Suzuki, K., Shimizu, H., Sugisaka, J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0384 · Cited by 294

Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program

Baldini, E., Lunghi, A., Cortesi, E., Turci, D., Signorelli, D., Stati, V., Melotti, B., Ricciuti, B., Frassoldati, A., Romano, G., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.014 · Cited by 43

Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab

Bouhlel, L., Doyen, J., Chamorey, E., Poudenx, M., Ilié, M., Gal, J., Guigay, J., Benzaquen, J., Marquette, C., Berthet, J., et al. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.019 · Cited by 26

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.019 · Cited by 377